This finding is consistent with that of He et al., who found that the levels of sLAG-3 in stage III-IV non-small-cell lung cancer (NSCLC) patients were significantly lower than those in stage I-II patients, and lower sLAG-3 may be related to worse tumor immune response in advanced disease patients (36). The gene discussed is LAG3; the disease is neoplasm.